Clinical Trials Logo

Esophageal Cancer clinical trials

View clinical trials related to Esophageal Cancer.

Filter by:

NCT ID: NCT00209716 Completed - Esophageal Cancer Clinical Trials

Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.

Start date: December 2003
Phase: Phase 1/Phase 2
Study type: Interventional

A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (TPF) in Pre-treated patients with metastatic esophageal cancer. The usefulness of the this regimen is evaluated by response rate, median survival time, and progression free survival.

NCT ID: NCT00209690 Completed - Esophageal Cancer Clinical Trials

Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.

Start date: October 2003
Phase: Phase 1/Phase 2
Study type: Interventional

A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (TPF) in untreated patients with metastatic esophageal cancer. The usefulness of the this regimen is evaluated by response rate, median survival time, and progression free survival.

NCT ID: NCT00201747 Completed - Esophageal Cancer Clinical Trials

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

Start date: September 2001
Phase: Phase 2
Study type: Interventional

To determine the most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas.

NCT ID: NCT00199849 Completed - Prostate Cancer Clinical Trials

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Start date: September 27, 2004
Phase: Phase 1
Study type: Interventional

To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.

NCT ID: NCT00197444 Completed - Esophageal Cancer Clinical Trials

Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer

Start date: January 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to clarify efficacy and toxicity of daily low-dose Nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation in patients with esophageal squamous cell carcinoma.

NCT ID: NCT00165464 Completed - Gastric Cancer Clinical Trials

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Start date: August 2001
Phase: Phase 2
Study type: Interventional

This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.

NCT ID: NCT00165061 Completed - Esophageal Cancer Clinical Trials

Multi-Center Prospective Randomized Trial Comparing Standard Esophagectomy Against Chemo-Radiotherapy for Treatment of Squamous Esophageal Cancer – Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)

Start date: July 2000
Phase: Phase 3
Study type: Interventional

A multicenter randomized comparison of primary esophagectomy against definitive chemoradiotherapy for the treatment of squamous esophageal cancer.

NCT ID: NCT00160875 Completed - Esophageal Cancer Clinical Trials

Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer

Start date: April 2009
Phase: Phase 2/Phase 3
Study type: Interventional

Cancer of the esophagus is a very serious cancer. Studies have shown that using chemotherapy and radiation before surgery is the most promising treatment approach, with one quarter to one half of tumors shrinking by 50% or more in size after chemotherapy and radiation. In patients who have a very good response to this treatment, survival following esophagectomy has increased, although the amount of increase has varied quite a bit between the different studies. Older studies have used the drugs Cisplatin and 5-fluoruracil. Although this combination of drugs has been beneficial, we wish to use a newer combination of drugs which may be more effective for esophageal cancer. The chemotherapy drugs used in this study are Cisplatin and Irinotecan. We also want to find out what side effects these drugs cause when given with radiation, and how often these side effects occur.

NCT ID: NCT00154804 Completed - Esophageal Cancer Clinical Trials

CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer

Start date: August 2001
Phase: Phase 2
Study type: Interventional

CCRT with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.

NCT ID: NCT00154700 Completed - Esophageal Cancer Clinical Trials

Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer

Start date: January 2001
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliative Chemotherapy.